Cialis and Cognitive Function: What the Evidence Actually Shows
A clinician-level review of tadalafil's effects on cerebral blood flow, cognition, and neurological outcomes, with primary-literature citations and dosing context.
Compounded vs Branded Cialis (Tadalafil): A Clinical Comparison
A comparison of compounded tadalafil vs branded Cialis covering bioequivalence, FDA regulatory status, dosing, cost, safety, and how to choose the right formulation for ED or BPH.
Cialis Hair and Skin Changes: What Tadalafil Actually Does to Your Body
A guide to tadalafil's documented effects on hair and skin, covering PDE5 inhibitor mechanisms, dermatologic adverse events, and what the primary literature says.
Cialis (Tadalafil) Metabolism and Energy Expenditure: What the Evidence Actually Shows
A deep dive into how tadalafil is absorbed, metabolized, and cleared, plus what the clinical evidence says about its effects on thermogenesis and energy expenditure in men.
Cialis (Tadalafil) After Bariatric Surgery: What Patients and Prescribers Need to Know
A clinician-level guide to tadalafil pharmacokinetics, dosing adjustments, drug interactions, and safety monitoring for patients who have undergone bariatric surgery, including Roux-en-Y gastric bypass and sleeve gastrectomy.
Cialis (Tadalafil) and the Kidneys: Renal Protection or Renal Risk?
A clinician-level review of tadalafil's effects on renal hemodynamics, proteinuria, CKD progression, and safety in patients with impaired kidney function. Covers dose adjustments, contraindications, and emerging data on renoprotection.
CJC-1295 Food & Supplement Interactions: What You Need to Know
A guide to how food, supplements, alcohol, and co-administered peptides affect CJC-1295 (modified GRF) absorption, GH pulsatility, and IGF-1 outcomes. Includes dosing timing windows, interaction tables, and HealthRX.com original decision framework.
CJC-1295 Future Formulations & Pipeline: What's Next for This GH Secretagogue
A physician-level review of CJC-1295 modified GRF future formulations, pipeline research, mechanism of action, and what evolving delivery technologies may mean for clinical practice.
CJC-1295 Older Adult (50 to 64) Dosing: A Clinical Guide
Evidence-based dosing guide for CJC-1295 (modified GRF) in adults aged 50 to 64, covering starting doses, titration, IGF-1 monitoring, and age-specific safety considerations including cardiovascular and polypharmacy risks.
CJC-1295 and Cognitive Function: What the Evidence Actually Shows
A clinical review of CJC-1295 modified GRF and its potential impact on cognitive function, including GH/IGF-1 signaling pathways, trial data, dosing considerations, and what patients should realistically expect.
CJC-1295 Liver Function Impact: What the Clinical Data Actually Show
A physician-level review of how CJC-1295 (modified GRF) affects liver enzymes, IGF-1 hepatic signaling, and clinical safety markers, with primary-literature citations.
CJC-1295 Pre-Surgery Hold Window: How Long to Stop Before Your Procedure
Evidence-based guidance on how long to hold CJC-1295 (modified GRF) before surgery, including GH physiology, anesthesia interactions, and restart timing from HealthRX.com physicians.
Biguanides Adverse-Event Management Protocols
A prescriber-level guide to managing metformin adverse events: GI tolerability, lactic acidosis risk stratification, B12 depletion monitoring, renal dose adjustment, and drug interactions, with citations to primary guidelines and trials.
Biguanides Drug-Drug Interaction Table: Complete Prescriber Reference
A clinician-level review of biguanide drug-drug interactions, covering metformin's DDI mechanisms, contraindications, iodinated contrast protocols, and dosing adjustments with pharmacokinetic data and guideline citations.
Bisphosphonates: How to Select the Right Agent Within the Class
A prescriber-level guide to choosing between alendronate, risedronate, ibandronate, zoledronic acid, and pamidronate based on indication, renal function, adherence profile, and fracture-reduction evidence.
Copper Peptides Adverse-Event Management Protocols
A clinical-level review of copper peptide pharmacology, adverse-event profiles, and management protocols for prescribers and dispensers. Covers GHK-Cu, dosing thresholds, skin and systemic reactions, and monitoring frameworks.
DPP-4 Inhibitors Billing & Prior-Auth Playbook
A prescriber-level guide to DPP-4 inhibitor pharmacology, place in T2D therapy, formulary strategy, prior-authorization requirements, and denial appeals, with trial data, dosing tables, and step-edit navigation.
Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table
Complete DDI table, prescribing guide, and clinical pharmacology review for GLP-1/GIP/glucagon triple agonists including retatrutide. Written at MD/PharmD level with primary-source citations.
Triple Agonists (GLP-1/GIP/Glucagon): How to Select the Right Agent Within the Class
A clinical guide to selecting among GLP-1/GIP/glucagon triple agonists, including retatrutide and emerging agents, with dosing, trial data, and patient-selection frameworks for prescribers and dispensers.
GH Secretagogues Billing & Prior-Auth Playbook
A prescriber-level guide to growth hormone secretagogue drug classes, coding strategy, prior-authorization tactics, and compounding compliance for ipamorelin, sermorelin, tesamorelin, and MK-677.
Healing Peptides: BPC-157, TB-500, and the Evidence Behind the Category
Understand what healing-peptide research actually measures, how BPC-157 and thymosin beta-4 differ, and why laboratory findings are not patient treatment protocols.
Basal Insulin Analogs Adverse-Event Management Protocols
A clinical reference for prescribers and pharmacists covering hypoglycemia, weight gain, injection-site reactions, and other adverse events associated with basal insulin analogs, with evidence-based management protocols and dosing guidance.
Rapid-Acting Insulin Analogs Drug-Drug Interaction Table: A Complete Prescriber Reference
A comprehensive drug-drug interaction table and class review for rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart). Pharmacokinetics, DDI mechanisms, clinical management strategies, and dosing guidance for prescribers and pharmacists.
NAD Precursors Adverse-Event Management Protocols
A clinician-level guide to managing adverse events from NAD precursors (NMN, NR, niacin), including dosing thresholds, monitoring parameters, drug interactions, and step-by-step mitigation protocols backed by primary-source evidence.
NAD Precursors: How to Select the Right Agent Within the Class
A clinician-level guide to NMN, NR, niacin, and nicotinamide, comparing pharmacokinetics, tissue delivery, clinical evidence, and practical prescribing decisions for NAD precursor therapy.
PCSK9 Inhibitors Monitoring Bundle: Complete Prescriber Reference
A board-reviewed clinical guide covering the PCSK9 inhibitor drug class, prescribing criteria, lipid and safety monitoring schedules, dose adjustments, and real-world outcomes data for evolocumab and alirocumab.
SERMs Billing & Prior-Auth Playbook: A Complete Prescriber Guide
A clinician-level guide to selective estrogen receptor modulator (SERM) billing codes, prior-authorization strategies, step-therapy requirements, and appeal tactics for tamoxifen, raloxifene, clomiphene, toremifene, ospemifene, and enclomiphene.
SERMs Special Populations Summary: Prescribing Across the Lifespan
A clinical-level review of selective estrogen receptor modulators (SERMs) in special populations including men, postmenopausal women, adolescents, and patients with renal or hepatic impairment. Covers enclomiphene, tamoxifen, raloxifene, ospemifene, and bazedoxifene with real doses, trials, and guidelines.
SERMs: Selecting the Right Agent Within the Class
A prescriber-level guide to choosing among tamoxifen, raloxifene, clomiphene, enclomiphene, toremifene, and ospemifene based on tissue selectivity, clinical indication, and patient-specific risk factors.
siRNA Lipid Therapeutics Adverse-Event Management Protocols
A prescriber-level guide to recognizing, grading, and managing adverse events with siRNA lipid therapeutics, inclisiran, fitusiran, and related agents, covering injection-site reactions, liver effects, bleeding risk, and off-target monitoring.
HMG-CoA Reductase Inhibitors Adverse-Event Management Protocols
A clinical reference for prescribers and pharmacists on managing statin adverse events: myopathy, hepatotoxicity, new-onset diabetes, and drug interactions, with specific monitoring thresholds and dose-adjustment protocols.
Testosterone Formulations Class Overview Monograph
A prescriber-level monograph covering every FDA-approved testosterone formulation: pharmacokinetics, dosing, monitoring, adverse effects, and clinical decision frameworks for hypogonadism management.
Wegovy vs Ozempic: Cost and Access Head-to-Head
A clinical comparison of Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5 to 2.0 mg) covering FDA-approved indications, weight-loss efficacy, list prices, insurance coverage, and how to access each drug in 2025.
Wegovy vs Ozempic: Switching Between Them Explained
Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5 to 2.0 mg) share the same molecule but differ in dose, indication, and titration schedule. Learn when switching makes sense, how to do it safely, and what the clinical data actually say.
Zepbound vs Ozempic: Switching Between Them, Efficacy, and What the Trials Show
A head-to-head comparison of tirzepatide (Zepbound) and semaglutide (Ozempic), covering weight loss, glycemic control, side effects, and a step-by-step guide to switching between them safely.
Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Switching Between Them
A clinical comparison of sildenafil generic tablets versus alprostadil injection (Caverject) and suppository (MUSE) for erectile dysfunction, including when and how to switch between them.
Viagra vs Sildenafil Generic: A Complete Guide to Switching Between Them
Viagra and generic sildenafil contain the same active molecule at the same doses. This guide explains bioequivalence, how to switch safely, dosing differences, cost comparisons, and what clinical evidence actually says.
Enclomiphene Citrate vs Jatenzo: Switching Between Them
A clinical comparison of enclomiphene citrate and Jatenzo (oral testosterone undecanoate) for male hypogonadism, including how and when to switch between them, with primary-source citations throughout.
Testosterone Enanthate vs AndroGel Side-Effect Profile Head-to-Head
A detailed clinical comparison of testosterone enanthate injections versus AndroGel (testosterone gel 1.62%) side-effect profiles, dosing, transfer risk, and which format suits different patients.
Egrifta (Tesamorelin) vs MK-677 (Ibutamoren): Cost and Access Head-to-Head
A direct clinical comparison of tesamorelin (Egrifta) and ibutamoren (MK-677) covering mechanism, evidence quality, cost, legal status, and who should use each compound.
BPC-157 vs TB-500: Why Cost and Access Claims Are Hard to Compare
Compare the research identities, evidence gaps, and advertised pricing assumptions behind BPC-157 and TB-500 without treating them as established therapies.
PT-141 (Bremelanotide) vs MOTS-c: Switching Between Them
A clinical comparison of PT-141 (bremelanotide) and MOTS-c, covering mechanisms, trial data, dosing, and how to approach switching between these two specialty peptides.
Thymosin Alpha-1 vs MOTS-c Side-Effect Profile Head-to-Head
A clinical comparison of thymosin alpha-1 (thymalfasin) and MOTS-c mitochondrial peptide side-effect profiles, mechanisms, dosing, and ideal patient selection, prepared by the HealthRX.com Editorial Team.
Liraglutide vs Trulicity: Long-Term Durability of Response
A head-to-head clinical comparison of liraglutide and dulaglutide (Trulicity) for long-term glycemic durability, weight loss, and cardiovascular outcomes. prepared by the HealthRX.com Editorial Team.
Rybelsus vs Trulicity: Combining the Two (Rationale + Risk)
A clinical comparison of oral semaglutide (Rybelsus) and dulaglutide (Trulicity): mechanism, trial evidence, and why combining two GLP-1 receptor agonists is not supported.
Saxenda vs Liraglutide in Special Populations: A Head-to-Head Clinical Comparison
A detailed head-to-head comparison of Saxenda (liraglutide 3 mg) versus liraglutide across special populations including patients with type 2 diabetes, adolescents, older adults, and those with renal or hepatic impairment. Includes trial data, dosing guidance, and switching protocols.
Wegovy vs Liraglutide: Titration Speed and Tolerability Compared
A clinical comparison of Wegovy (semaglutide 2.4 mg) and liraglutide on titration schedules, GI tolerability, weight-loss efficacy, and switching protocols, with primary-source citations throughout.
Wegovy vs Ozempic: Real-World Evidence Comparison
A breakdown of Wegovy (semaglutide 2.4 mg) versus Ozempic (semaglutide 0.5 to 2.0 mg) using STEP trial data, SUSTAIN trial data, and real-world cohort evidence, including weight loss outcomes, cardiovascular effects, side-effect profiles, and switching guidance.
Zepbound vs Liraglutide Special Populations Head-to-Head
A clinical comparison of tirzepatide (Zepbound) and liraglutide across special populations including patients with T2D, PCOS, CKD, older adults, and those considering a switch. Backed by SURMOUNT-1, SCALE Obesity, and real-world data.
Zepbound vs Saxenda: Combining the Two (Rationale + Risk)
A clinical breakdown of Zepbound (tirzepatide) vs Saxenda (liraglutide 3 mg), why combining them is not recommended, the evidence behind each drug, and how to safely switch between them.
Zepbound vs Saxenda: What to Do When One Fails
A clinical comparison of tirzepatide (Zepbound) and liraglutide (Saxenda) covering efficacy data, failure definitions, and a step-by-step switching protocol for patients and prescribers.
Dapagliflozin vs Metformin: Special Population Safety Guide
Dapagliflozin favors heart failure, CKD, and metformin-contraindicated patients; metformin stays first-line otherwise. Compare mechanisms, risks, and HbA1c effects.
Jardiance vs Metformin: What to Do When One Fails
A clinical comparison of empagliflozin (Jardiance) and metformin for type 2 diabetes, with evidence-based guidance on what to do when either drug stops working or causes intolerable side effects.
Metformin vs Lantus (Insulin Glargine): Real-World Evidence Comparison
A head-to-head look at metformin versus insulin glargine (Lantus) across clinical trials and real-world data, covering HbA1c reduction, weight, hypoglycemia risk, cardiovascular outcomes, and when clinicians switch between them.
Rapamycin (Sirolimus) vs Low-Dose Naltrexone: Titration Speed and Tolerability Compared
A clinical comparison of rapamycin (sirolimus) and low-dose naltrexone (LDN) as off-label longevity agents, covering titration approaches, tolerability, monitoring, and the evidence gaps that matter for decision-making.
Cialis vs Tadalafil Generic: Real-World Evidence Comparison
A thorough, citation-dense comparison of brand Cialis and generic tadalafil covering pharmacokinetics, clinical trial data, real-world effectiveness, cost, and switching guidance for men with ED or BPH.
Cialis vs Tadalafil Generic: Special Populations Head-to-Head
A clinical deep-dive comparing brand Cialis to generic tadalafil in special populations including men with diabetes, cardiovascular disease, BPH, renal impairment, and older adults. Dosing, safety, and switching guidance from named trials and guidelines.
Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): What to Do When One Fails
A clinical comparison of tadalafil generic and vardenafil (Levitra/Staxyn) for erectile dysfunction, including what evidence says about switching when one PDE5 inhibitor stops working.
Testosterone Cypionate vs Jatenzo: What to Do When One Fails
A comparison of injectable testosterone cypionate and oral Jatenzo (testosterone undecanoate), including how to recognize failure, when to switch, and how to manage the transition safely.
Testosterone Cypionate vs Testosterone Enanthate: Combining the Two (Rationale + Risk)
A clinical comparison of testosterone cypionate and testosterone enanthate for men on TRT, including the evidence behind combining them, pharmacokinetic differences, and safety considerations.